CD40 Ligand Market to see Rapid Growth by 2028
The global CD40 Ligand market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). CD154, also known as CD40 ligand or CD40L, is a member of the TNF superfamily of molecules that is largely expressed on activated T cells. It attaches to CD40 (protein) on antigen-presenting cells (APC), resulting in a variety of consequences depending on the kind of target cell.CD40 expression has also been found in non-hematopoietic cells, including bladder cancer cells, where the CD40 antigen was first discovered, as well as ovarian, breast, nasopharyngeal, liver, and cervical carcinoma cells.
To Request a Sample of our Report on CD40 Ligand Market: https://www.omrglobal.com/request-sample/cd40-ligand-market
Ovarian cancer is the most common type of cancer
which has higher response rates as compared to those women who only received a
checkpoint inhibitor. It causes the abnormality of certain cells in the ovary.
Such cancers can arise in the epithelial cells that cover the ovarian surface.
However, a significant improvement has been observed in the therapies for the
treatment of cancer, it is still one of the major causes of mortalities
globally. As per the American Cancer Society in 2016, around 22,000 women in
the US received a new diagnosis of ovarian cancer, and around 14,000 women
succumbed to this disease. The oncolytic virus therapy serves as a promising
approach for the treatment of cancer. Bladder cancer is the tenth most common
cancer across the globe. In 2018, there were 17 million new cases of bladder
cancer across the globe. As per Cancer Research UK, the incidence of cancer is
estimated to reach 62% during 2018-2040 across the globe. Bladder cancer is
considered the fourth most common cancer in men whereas it is the least common
cancer in women. Further, there is an increasing incidence of bladder cancer in
emerging countries such as China and India attributed to increasing smoking and
tobacco consumption. In India, bladder cancer is considered the 18th most
common cancer in 2018. As per the National Institute of cancer prevention and
research (NICPR), there were 18,296 new cases of bladder cancer in India in
2018. Further, there were 10,231 mortalities that were recorded in 2018.
Market Coverage
·
The market number available for – 2021-2028
·
Base year- 2021
·
Forecast period- 2022-2028
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Targovax ASA, and Bristol-Myers Squibb Company,
among others.
A
full Report of CD40 Ligand Market is Available @ https://www.omrglobal.com/industry-reports/cd40-ligand-market
Global CD40 Ligand Market Report by Segment
By Type
·
ISF-35
·
LOAd700
·
MEDI-4920
·
MegaCD40L
·
Others
By Application
·
Hepatitis B
·
Bladder Cancer
·
Liver Cancer
·
Ovarian Cancer
·
Others
Global CD40 Ligand Market Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no:
+91 7803040404
Comments
Post a Comment